Collaboration agreement between French firms Vect-Horus and AAA

French biotech company Vect-Horus, specializing in the development of vector molecules for the central nervous system (CNS), has signed a scientific collaboration agreement with French molecular nuclear medicine firm Advanced Accelerator Applications (AAA). Financial terms of the deal have not been disclosed.

Vect-Horus said the agreement is part of its strategy to leverage its technological platform by entering into research and product development agreements with pharmaceutical and biopharmaceutical companies to generate patentable New Chemical Entities (NCEs) based on its partner’s drug or imaging candidates.

Vect-Horus co-founder Alexandre Tokay said: “We are proud to have signed this agreement with a European leader in molecular nuclear medicine. We believe that this scientific collaboration will be fruitful for both parties and open new avenues in the treatment of brain diseases.”

AAA chief executive Stefano Buono added: “We find Vect-Horus’ technology very interesting and see real potential in molecular nuclear diagnostics.”

Vect-Horus is specialized in the development of vector molecules that allow delivery of therapeutic and imaging molecules in different organs and cell types, in particular in the central nervous system. The brain vascular system, known as the blood brain barrier (BBB), considerably restricts the delivery of drugs and imaging agents from blood to nervous tissue. The BBB is largely responsible for the high attrition rate of the pharmaceutical industry in the CNS therapeutic area.